Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme
The DOI matches its Crossref record; 124 of the 125 references it cites were found in a registry or an index.
Abstract
Glioblastoma multiforme (GBM) is the most common primary malignancy in the brain and confers a uniformly poor prognosis. Despite decades of research on the topic, limited progress has been made to improve the poor survival associated with this disease. GBM arises de novo (primary GBM) or via dedifferentiation of lower grade glioma (secondary GBM). While distinct mutations are predominant in each subtype, alterations of tumor suppressor p53 are the most common, seen in 25-30 % of primary GBM and 60-70 % of secondary GBM. Various roles of p53 that protect against neoplastic transformation include modulation of cell cycle, DNA repair, apoptosis, senescence, angiogenesis, and metabolism, resulting in an extremely complex signaling network. Mutations of p53 in GBM are most common in the DNA-binding domain, namely within six hotspot mutation sites (codons 175, 245, 248, 249, 273, and 282). These alterations generally result in loss-of-function, gain-of-function, and dominant-negative mutational effects for p53, however, the distinct effect of these mutation types in GBM pathogenesis remain unclear. Signaling alterations downstream from p53 (e.g., MDM2, MDM4, INK4/ARF), p53 isoforms (e.g., p63, p73), and microRNAs (e.g., miR-34) also play critical roles in modulating the p53 pathway. Despite novel mouse models of GBM showing that p53 combined with other mutation generate tumors de novo, the role of p53 as a molecular marker of GBM remains controversial with most studies failing to show an association with prognosis. Regarding treatment in GBM, p53 targeted-gene therapy and vaccinations have reached phase I clinical trials while therapeutic drugs are still in preclinical development. This review aims to discuss the most recent findings regarding the impact of p53 mutations on GBM pathogenesis, prognosis, and treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MDM2 targets p53 for degradation, acting as a negative regulator [27,41].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [27]
In the citing paper
“p53 inactivation is correlated with a more invasive [30], less apoptotic [31], more proliferative [27], and more stem-like [28] phenotype.”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [27]
In the citing paper
“Although mut-p53 has been correlated to poorer prognosis in breast and other cancers [32], the mutational status of TP53 and its various pathway elements (ARF-MDM2/4) has not been correlated with survival in GBM, despite the high mutation frequency [27,32,33,34].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [27]
In the citing paper
“MDM2 amplifications have not been shown to correlate with GBM survival and/or prognosis [27,32,33,34].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [27]
In the citing paper
“Amplification of MDM2 and MDM4 can inactivate p53, leading to loss of various tumor suppressor functions including growth arrest, apoptosis, DNA repair, and senescence [27,41].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [27]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673 · cited 1×
“Recent studies have demonstrated the transformation of differentiated fibroblasts by adenovirus-mediated transfection of oct4, sox2, klf4, and c-Myc into induced pluripotent stem cells (iPSC) that possess a multipotent state and potential to differentiate along a variety of cell lineages [62].”
BackgroundComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 1×
“Inactivation of p53 can also occur by multiplication of the MDM2 gene (an E3 ubiquitin ligase which targets p53 for degradation), viral infection, deletion of the p14 gene, and mislocalization of p53 to the cytoplasm [12].”
BackgroundAn Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 6×
“Approximately 95 % of all p53 mutations occur in the core DNA-binding domain, 28 % of all mutations occur at p53 hotspot mutation sites (codons 175, 245, 248, 249, 273, and 282), and 75 % of all mutations are missense mutations [5, 14].”
BackgroundInfluentialIsolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma
Galli, R., Binda, E., Orfanelli, U., Cipelletti, B., Gritti, A., De Vitis, S., Fiocco, R., Foroni, C., Dimeco, F., & Vescovi, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1364 · Cited by 2,570 · cited 1×
“These findings are relevant in the context of recently discovered CSCs in GBM that may account for this tumor’s origin, proliferative capacity, and recurrence [9, 61].”
BackgroundCrystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551 · cited 1×
“Hotspot mutations are located near the protein-DNA interface and most commonly including contact mutants/class I mutation (R248, R273) that interact with DNA, and structural mutants/class II mutations (R175, R245, R249, R282) that play critical roles in stabilizing the structure of the DNAbinding interface [13, 29].”
BackgroundChromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,066
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921 · cited 1×
“Refinement of the response element for p53 has helped identify potential targets for p53 based on the p53 consensus site that consists of two copies of RRRCA/TT/AGYYY (R: purine, Y: pyrimidine) [17].”
BackgroundThe multistep nature of cancer
Vogelstein, B., & Kinzler, K. W. (1993) · Trends in Genetics · doi:10.1016/0168-9525(93)90209-z · Cited by 1,853
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
Linking the p53 tumour suppressor pathway to somatic cell reprogramming
Kawamura, T., Suzuki, J., Wang, Y. V., Menendez, S., Morera, L. B., Raya, A., Wahl, G. M., & Belmonte, J. C. I. (2009) · Nature · doi:10.1038/nature08311 · Cited by 1,115
Cytoplasmic functions of the tumour suppressor p53
Green, D. R., & Kroemer, G. (2009) · Nature · doi:10.1038/nature07986 · Cited by 1,106 · cited 1×
“In addition, p53 mediates several cytoplasmic, non-transcription roles regulating apoptosis and autophagy [18].”
BackgroundGain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069 · cited 1×
“The accumulation of DNA damage in a mutant p53 environment as can occur in the hypoxic microenvironment of GBM can also synergistically increase mutant p53 expression [21].”
BackgroundRestoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity
Marión, R. M., Strati, K., Li, H., Murga, M., Blanco, R., Ortega, S., Fernandez-Capetillo, O., Serrano, M., & Blasco, M. A. (2009) · Nature · doi:10.1038/nature08287 · Cited by 1,028
p53 and Human Cancer: The First Ten Thousand Mutations
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60785-x · Cited by 986 · cited 1×
“P53 is in fact a tumor suppressor and transcription factor mutated in approximately 50 % of tumors where its mutations commonly result in constitutive expression [15].”
BackgroundThe Ink4/Arf locus is a barrier for iPS cell reprogramming
Li, H., Collado, M., Villasante, A., Strati, K., Ortega, S., Cañamero, M., Blasco, M. A., & Serrano, M. (2009) · Nature · doi:10.1038/nature08290 · Cited by 968
Long-term survival with glioblastoma multiforme
Krex, D., Klink, B., Hartmann, C., von Deimling, A., Pietsch, T., Simon, M., Sabel, M., Steinbach, J. P., Heese, O., Reifenberger, G., et al. (2007) · Brain · doi:10.1093/brain/awm204 · Cited by 887
TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes
Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884 · cited 1×
“fr) demonstrated that loss of transactivation and dominantnegative effects are the main effectors of p53 mutation pattern and tumor phenotype in human cancers [33].”
Backgroundp53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression
Lin, T., Chao, C., Saito, S., Mazur, S. J., Murphy, M. E., Appella, E., & Xu, Y. (2005) · Nature Cell Biology · doi:10.1038/ncb1211 · Cited by 859
Immortalization eliminates a roadblock during cellular reprogramming into iPS cells
Utikal, J., Polo, J. M., Stadtfeld, M., Maherali, N., Kulalert, W., Walsh, R. M., Khalil, A., Rheinwald, J. G., & Hochedlinger, K. (2009) · Nature · doi:10.1038/nature08285 · Cited by 836
p53 isoforms can regulate p53 transcriptional activity
Bourdon, J.-C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. P., Saville, M. K., & Lane, D. P. (2005) · Genes & Development · doi:10.1101/gad.1339905 · Cited by 810
Pharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 799
A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis
Adorno, M., Cordenonsi, M., Montagner, M., Dupont, S., Wong, C., Hann, B., Solari, A., Bobisse, S., Rondina, M. B., Guzzardo, V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.01.039 · Cited by 782 · cited 1×
“Downregulation of p63/p73 can recapitulate mutant p53 phenotypes while the overexpression of some p63/p73 isotypes can paradoxically negate mutant p53 phenotypes [36, 38, 39].”
Backgroundp53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation
Zheng, H., Ying, H., Yan, H., Kimmelman, A. C., Hiller, D. J., Chen, A.-J., Perry, S. R., Tonon, G., Chu, G. C., Ding, Z., et al. (2008) · Nature · doi:10.1038/nature07443 · Cited by 767 · cited 1×
“However, several recent molecular models of GBM have suggested that mutations of other genes are also concomitantly necessary for GBM formation, indicating that multiple genetic alterations may be required for clinically detectable tumor development [3, 4].”
BackgroundSmall molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors
Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 750
Malatesta, P., Hack, M. A., Hartfuss, E., Kettenmann, H., Klinkert, W., Kirchhoff, F., & Götz, M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00116-8 · Cited by 746
Structural Biology of the Tumor Suppressor p53
Joerger, A. C., & Fersht, A. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.060806.091238 · Cited by 693 · cited 1×
“Mutant p53 can occupy at least five thermodynamic states, including several “mutant” conformations thought to influence specific signals involving tetramerization, DNA binding, and differential gene expression; however, mutation of p53 locks it to a conformation resulting in improper recognition of DNA elements [13, 3…”
BackgroundMicroRNA-34a Inhibits Glioblastoma Growth by Targeting Multiple Oncogenes
Li, Y., Guessous, F., Zhang, Y., DiPierro, C., Kefas, B., Johnson, E., Marcinkiewicz, L., Jiang, J., Yang, Y., Schmittgen, T. D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0529 · Cited by 614 · cited 2×
“One study showed that miR-34a was downregulated in glioma compared to normal brain, especially glioma with mutant p53 compared to wild-type [24].”
BackgroundResultRescuing the function of mutant p53
Bullock, A. N., & Fersht, A. R. (2001) · Nature Reviews Cancer · doi:10.1038/35094077 · Cited by 568 · cited 2×
“Hotspot mutations are located near the protein-DNA interface and most commonly including contact mutants/class I mutation (R248, R273) that interact with DNA, and structural mutants/class II mutations (R175, R245, R249, R282) that play critical roles in stabilizing the structure of the DNAbinding interface [13, 29].”
BackgroundHolland, E. C., Hively, W. P., DePinho, R. A., & Varmus, H. E. (1998) · Genes & Development · doi:10.1101/gad.12.23.3675 · Cited by 556
Flores, E. R., Sengupta, S., Miller, J. B., Newman, J. J., Bronson, R., Crowley, D., Yang, A., McKeon, F., & Jacks, T. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.019 · Cited by 502 · cited 1×
“Downregulation of p63/p73 can recapitulate mutant p53 phenotypes while the overexpression of some p63/p73 isotypes can paradoxically negate mutant p53 phenotypes [36, 38, 39].”
BackgroundChiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., Kracher, J., Grossman, S. A., Fisher, J. D., Carson, K., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.021 · Cited by 436
Di Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., Blandino, G., & Piaggio, G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.013 · Cited by 418 · cited 1×
“Mutant p53 can also regulate single-stranded DNA-binding protein recruitment such as SP1 [48] and p300 [49] to influence epigenetic modification.”
Backgroundp53 suppresses the self-renewal of adult neural stem cells
Meletis, K., Wirta, V., Hede, S.-M., Nistér, M., Lundeberg, J., & Frisén, J. (2006) · Development · doi:10.1242/dev.02208 · Cited by 413
Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406
Lang, F. F., Bruner, J. M., Fuller, G. N., Aldape, K., Prados, M. D., Chang, S., Berger, M. S., McDermott, M. W., Kunwar, S. M., Junck, L. R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.21.13.2508 · Cited by 395
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 387
IDH mutations in glioma and acute myeloid leukemia
Dang, L., Jin, S., & Su, S. M. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.07.002 · Cited by 370
Werner, H., Karnieli, E., Rauscher, F. J., & LeRoith, D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8318 · Cited by 370 · cited 1×
“In other studies, mutant p53 has been able to transactivate potent growth factor genes, such as insulin-like growth factor receptor 1 [53] and IGF2 [54], genes involved in cell cycle such as PCNA [55], and genes involved in inflammatory signaling such as nuclear factor kappa B (NF-κB) [56].”
BackgroundShaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm
Soussi, T., & Wiman, K. G. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.001 · Cited by 368
Selivanova, G., Iotsova, V., Okan, I., Fritsche, M., Ström, M., Groner, B., Grafström, R. C., & Wiman, K. G. (1997) · Nature Medicine · doi:10.1038/nm0697-632 · Cited by 343 · cited 1×
“Class II mutations generate a more severe pathological phenotype than class I mutations and are due to irreversible conformation changes, which cannot be restored to wild-type configuration by p53 reactivating treatments [30, 31].”
BackgroundLiu, G., Parant, J. M., Lang, G., Chau, P., Chavez-Reyes, A., El-Naggar, A. K., Multani, A., Chang, S., & Lozano, G. (2004) · Nature Genetics · doi:10.1038/ng1282 · Cited by 325
Uhrbom, L., Dai, C., Celestino, J., Rosenblum, M. K., Fuller, G. N., & Holland, E. C. (2002) · PubMed · Cited by 322
The Guardian's Little Helper: MicroRNAs in the p53 Tumor Suppressor Network
He, X., He, L., & Hannon, G. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2672 · Cited by 317 · cited 2×
“Recent studies have shown that p53 can alter expression of multiple genes involved in cell cycle arrest, apoptosis, and cellular senescence through the transactivation of microRNA-34a (miR-34a), miR-34b, and miR-34c [22, 23].”
BackgroundGene expression profiling and genetic markers in glioblastoma survival
Rich, J. N., Hans, C., Jones, B., Iversen, E. S., McLendon, R. E., Rasheed, B. K. A., Dobra, A., Dressman, H. K., Bigner, D. D., Nevins, J. R., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3936 · Cited by 316
Neural stem cells in mammalian development
Merkle, F. T., & Alvarez-Buylla, A. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.09.008 · Cited by 312
microRNA-34a is tumor suppressive in brain tumors and glioma stem cells
Guessous, F., Zhang, Y., Kofman, A., Catania, A., Li, Y., Schiff, D., Purow, B., & Abounader, R. (2010) · Cell Cycle · doi:10.4161/cc.9.6.10987 · Cited by 306 · cited 1×
“Several key signaling molecules have been implicated in glioma as regulated by miR-34a, including Notch-1, Notch-2, CDK6, and sirtuin 1 [24, 25].”
BackgroundThe Origins and Evolution of the p53 Family of Genes
Belyi, V. A., Ak, P., Markert, E., Wang, H., Hu, W., Puzio-Kuter, A., & Levine, A. J. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001198 · Cited by 292 · cited 1×
“In addition to inhibiting p63 and p73, mutant p53 gain-offunction has been shown to induce direct alterations in genetic expression [27, 41, 42].”
Backgroundp53 mutation heterogeneity in cancer
Soussi, T., & Lozano, G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.190 · Cited by 275
The promises and perils of p53
Krizhanovsky, V., & Lowe, S. W. (2009) · Nature · doi:10.1038/4601085a · Cited by 274
Mutant p53: an oncogenic transcription factor
Strano, S., Dell'Orso, S., Di Agostino, S., Fontemaggi, G., Sacchi, A., & Blandino, G. (2007) · Oncogene · doi:10.1038/sj.onc.1210296 · Cited by 269 · cited 2×
“Genes thus discovered to be upregulated by mutant p53, include those involving oncogenesis such as MYC, common drivers of gliomagenesis such as epidermal growth factor receptor (EGFR), and also the well known chemotherapy resistance molecule MDR1 (ATP-binding cassette B1) [41, 51, 52].”
BackgroundWang, Y., Yang, J., Zheng, H., Tomasek, G. J., Zhang, P., McKeever, P. E., Lee, E. Y.-H. P., & Zhu, Y. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.001 · Cited by 250 · cited 1×
“However, several recent molecular models of GBM have suggested that mutations of other genes are also concomitantly necessary for GBM formation, indicating that multiple genetic alterations may be required for clinically detectable tumor development [3, 4].”
BackgroundA GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers
Stecca, B., & Ruiz i Altaba, A. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.16 · Cited by 233
Popowicz, G. M., Czarna, A., Wolf, S., Wang, K., Wang, W., Dömling, A., & Holak, T. A. (2010) · Cell Cycle · doi:10.4161/cc.9.6.10956 · Cited by 230
Regulatory Approvals of Pediatric Oncology Drugs: Previous Experience and New Initiatives
Hirschfeld, S., Ho, P. T. C., Smith, M., & Pazdur, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.138 · Cited by 229
Ubiquitination and Degradation of Mutant p53
Lukashchuk, N., & Vousden, K. H. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00050-07 · Cited by 223 · cited 1×
“MDM2 downregulates p53 activity while p53 expression simultaneously upregulates MDM2, indicating a potent negative feedback loop modulating overall p53 expression [19].”
BackgroundWu, G., Nomoto, S., Hoque, M. O., Dracheva, T., Osada, M., Lee, C. R., Dong, S. M., Guo, Z., Benoit, N. E., Cohen, Y., et al. (2003) · PubMed · Cited by 221
Gil-Perotin, S., Marin-Husstege, M., Li, J., Soriano-Navarro, M., Zindy, F., Roussel, M. F., Garcia-Verdugo, J.-M., & Casaccia-Bonnefil, P. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3970-05.2006 · Cited by 215
Jacques, T. S., Swales, A., Brzozowski, M. J., Henriquez, N. V., Linehan, J. M., Mirzadeh, Z., O' Malley, C., Naumann, H., Alvarez‐Buylla, A., & Brandner, S. (2010) · The EMBO Journal · doi:10.1038/emboj.2009.327 · Cited by 214
Transcription regulation by mutant p53
Weisz, L., Oren, M., & Rotter, V (2007) · Oncogene · doi:10.1038/sj.onc.1210294 · Cited by 207 · cited 1×
“In addition to inhibiting p63 and p73, mutant p53 gain-offunction has been shown to induce direct alterations in genetic expression [27, 41, 42].”
BackgroundTargeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function
de Vries, A., Flores, E. R., Miranda, B., Hsieh, H.-M., van Oostrom, C. T. M., Sage, J., & Jacks, T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052713099 · Cited by 207
TP53: a key gene in human cancer
Guimaraes, D. P., & Hainaut, P. (2002) · Biochimie · doi:10.1016/s0300-9084(01)01356-6 · Cited by 203 · cited 1×
“Approximately 95 % of all p53 mutations occur in the core DNA-binding domain, 28 % of all mutations occur at p53 hotspot mutation sites (codons 175, 245, 248, 249, 273, and 282), and 75 % of all mutations are missense mutations [5, 14].”
BackgroundFelsberg, J., Rapp, M., Loeser, S., Fimmers, R., Stummer, W., Goeppert, M., Steiger, H.-J., Friedensdorf, B., Reifenberger, G., & Sabel, M. C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2801 · Cited by 203
Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs
Bykov, V. J. N., Issaeva, N., Zache, N., Shilov, A., Hultcrantz, M., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501664200 · Cited by 202
Bossi, G., Lapi, E., Strano, S., Rinaldo, C., Blandino, G., & Sacchi, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209026 · Cited by 202
High metastatic potential in mice inheriting a targeted p53 missense mutation
Liu, G., McDonnell, T. J., Montes de Oca Luna, R., Kapoor, M., Mims, B., El-Naggar, A. K., & Lozano, G. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.8.4174 · Cited by 199
Frazier, M. W., He, X., Wang, J., Gu, Z., Cleveland, J. L., & Zambetti, G. P. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3735 · Cited by 194 · cited 1×
“Genes thus discovered to be upregulated by mutant p53, include those involving oncogenesis such as MYC, common drivers of gliomagenesis such as epidermal growth factor receptor (EGFR), and also the well known chemotherapy resistance molecule MDR1 (ATP-binding cassette B1) [41, 51, 52].”
BackgroundTargeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils
Stegh, A. H. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.643299 · Cited by 194 · cited 1×
“More than 30 years of research on tumor suppressor p53 have yielded over 50,000 publications making p53 one of the most studied proteins in science and significant in the understanding ofGBM [10].”
BackgroundThe Isoforms of the p53 Protein
Khoury, M. P., & Bourdon, J.-C. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000927 · Cited by 191 · cited 1×
“P63/p73 has multiple DNA, mRNA and protein isoforms similarly to the large variety in p53 isoforms [35].”
BackgroundTranscriptional Activation of the Human Epidermal Growth Factor Receptor Promoter by Human p53
Ludes-Meyers, J. H., Subler, M. A., Shivakumar, C. V., Munoz, R. M., Jiang, P., Bigger, J. E., Brown, D. R., Deb, S. P., & Deb, S. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.11.6009 · Cited by 182 · cited 1×
“Genes thus discovered to be upregulated by mutant p53, include those involving oncogenesis such as MYC, common drivers of gliomagenesis such as epidermal growth factor receptor (EGFR), and also the well known chemotherapy resistance molecule MDR1 (ATP-binding cassette B1) [41, 51, 52].”
BackgroundGenetic profile of astrocytic and oligodendroglial gliomas
Ohgaki, H., & Kleihues, P. (2011) · Brain Tumor Pathology · doi:10.1007/s10014-011-0029-1 · Cited by 167 · cited 1×
“Glioblastomamultiforme (GBM) is aWorldHealthOrganization grade IVmalignant astrocytoma categorized clinicopathologically into primary GBM, which arises de novo, and secondary GBM, which arises from lower grade glioma [1, 2].”
BackgroundOry, K., Legros, Y., Auguin, C., & Soussi, T. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06656.x · Cited by 163 · cited 1×
“Class II mutations generate a more severe pathological phenotype than class I mutations and are due to irreversible conformation changes, which cannot be restored to wild-type configuration by p53 reactivating treatments [30, 31].”
BackgroundPrognostic impact of molecular markers in a series of 220 primary glioblastomas
Houillier, C., Lejeune, J., Benouaich‐Amiel, A., Laigle–Donadey, F., Crinière, E., Mokhtari, K., Thillet, J., Delattre, J., Hoang‐Xuan, K., & Sanson, M. (2006) · Cancer · doi:10.1002/cncr.21819 · Cited by 159
Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma
Stegh, A. H., Kim, H., Bachoo, R. M., Forloney, K. L., Zhang, J., Schulze, H., Park, K., Hannon, G. J., Yuan, J., Louis, D. N., et al. (2007) · Genes & Development · doi:10.1101/gad.1480007 · Cited by 153
Current Progress on Understanding MicroRNAs in Glioblastoma Multiforme
Karsy, M., Arslan, E., & Moy, F. (2012) · Genes & Cancer · doi:10.1177/1947601912448068 · Cited by 151 · cited 2×
“Recent studies have shown that p53 can alter expression of multiple genes involved in cell cycle arrest, apoptosis, and cellular senescence through the transactivation of microRNA-34a (miR-34a), miR-34b, and miR-34c [22, 23].”
BackgroundSelf-citationVikhanskaya, F., Lee, M. K., Mazzoletti, M., Broggini, M., & Sabapathy, K. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm099 · Cited by 145 · cited 11×
“In one study, mean survival with p53 mutation (HR: 2.05, p=0.28) was slightly higher than PTEN (HR: 1.16, p= 0.79) and p16/INK4A (HR: 0.58, p=0.39) but was not prognostically significant in post hoc, age-adjusted regression models [94].”
BackgroundInfluentialAhmed, A. U., Tyler, M. A., Thaçi, B., Alexiades, N. G., Han, Y., Ulasov, I. V., & Lesniak, M. S. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200161f · Cited by 137
p53, p63 and p73 – solos, alliances and feuds among family members
Moll, U. M., Erster, S. H., & Zaika, A. (2001) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(01)00036-1 · Cited by 136 · cited 2×
“Downregulation of p63/p73 can recapitulate mutant p53 phenotypes while the overexpression of some p63/p73 isotypes can paradoxically negate mutant p53 phenotypes [36, 38, 39].”
BackgroundNeural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo
Tyler, M. A., Ulasov, I. V., Sonabend, A. M., Nandi, S., Han, Y., Marler, S., Roth, J., & Lesniak, M. S. (2009) · Gene Therapy · doi:10.1038/gt.2008.165 · Cited by 128
Cancer stem cells and “stemness” genes in neuro-oncology
Nicolis, S. K. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.08.022 · Cited by 126
Zalcenstein, A., Stambolsky, P., Weisz, L., Müller, M., Wallach, D., Goncharov, T. M., Krammer, P. H., Rotter, V., & Oren, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206724 · Cited by 123 · cited 1×
“On the other hand, mutant p53 downregulates a variety of genes, many of which have play critical roles in GBM, including: CD95/Fas/Apo1 [57], transforming growth factor, beta receptor II [58], caspase-3 [59], p21, GADD45 (growth arrest and DNA damage-inducible), PERP (p53 apoptosis effector related to PMP22) and PTEN…”
BackgroundKarsy, M. J., Gelbman, M., Shah, P., Balumbu, O., MOY, F. H., & Arslan, E. (2012) · Folia Neuropathologica · doi:10.5114/fn.2012.32361 · Cited by 116 · cited 1×
“Glioblastomamultiforme (GBM) is aWorldHealthOrganization grade IVmalignant astrocytoma categorized clinicopathologically into primary GBM, which arises de novo, and secondary GBM, which arises from lower grade glioma [1, 2].”
BackgroundSelf-citationModulation of Gene Expression by Tumor-Derived p53 Mutants
Scian, M. J., Stagliano, K. E. R., Ellis, M. A., Hassan, S., Bowman, M., Miles, M. F., Deb, S. P., & Deb, S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1568 · Cited by 116 · cited 2×
“In other studies, mutant p53 has been able to transactivate potent growth factor genes, such as insulin-like growth factor receptor 1 [53] and IGF2 [54], genes involved in cell cycle such as PCNA [55], and genes involved in inflammatory signaling such as nuclear factor kappa B (NF-κB) [56].”
BackgroundDavison, T. S., Yin, P., Nie, E., Kay, C. M., & Arrowsmith, C. H. (1998) · Oncogene · doi:10.1038/sj.onc.1202062 · Cited by 112
Demma, M., Maxwell, E., Ramos, R., Liang, L., Li, C., Hesk, D., Rossman, R., Mallams, A., Doll, R., Liu, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.083469 · Cited by 107
p53 regulates the self-renewal and differentiation of neural precursors
Armesilla-Diaz, A., Bragado, P., del Valle, I., Cuevas, E. P., Lazaro‐Trueba, I., Martin, C., Cigudosa, J. C., & Silva, A. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.10.052 · Cited by 105
What is the clinical value of cancer stem cell markers in gliomas?
Dahlrot, R. H., Hermansen, S. K., Hansen, S., & Kristensen, B. W. (2013) · Europe PMC (PubMed Central) · Cited by 101
Gualberto, A., & Baldwin, A. S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.34.19680 · Cited by 101 · cited 3×
“Mutant p53 can also regulate single-stranded DNA-binding protein recruitment such as SP1 [48] and p300 [49] to influence epigenetic modification.”
BackgroundLomax, M. E., Barnes, D. M., Hupp, T. R., Picksley, S. M., & Camplejohn, R. (1998) · Oncogene · doi:10.1038/sj.onc.1201974 · Cited by 100
Mutant p53 targeting by the low molecular weight compound STIMA‐1
Zache, N., Lambert, J. M. R., Rökaeus, N., Shen, J., Hainaut, P., Bergman, J., Wiman, K. G., & Bykov, V. J. N. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.02.004 · Cited by 96
PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations
Li, Y., Guessous, F., Kwon, S., Kumar, M., Ibidapo, O., Fuller, L., Johnson, E., Lal, B., Hussaini, I., Bao, Y., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1963 · Cited by 95 · cited 1×
“Mutations of PTEN, also common in GBM, can promote tumor formation in a mutant p53 background by preventing MDM2-mediated degradation of mutant p53 [20].”
BackgroundLee, Y. I., Lee, S., Das, G. C., Park, U. S., Park, S. M., & Lee, Y. I. (2000) · Oncogene · doi:10.1038/sj.onc.1203694 · Cited by 94 · cited 1×
“In other studies, mutant p53 has been able to transactivate potent growth factor genes, such as insulin-like growth factor receptor 1 [53] and IGF2 [54], genes involved in cell cycle such as PCNA [55], and genes involved in inflammatory signaling such as nuclear factor kappa B (NF-κB) [56].”
BackgroundBlough, M. D., Beauchamp, D. C., Westgate, M. R., Kelly, J. J., & Cairncross, J. G. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0283-9 · Cited by 94
Bossi, G., Marampon, F., Maor-Aloni, R., Zani, B., Rotter, V., Oren, M., Strano, S., Blandino, G., & Sacchi, A. (2008) · Cell Cycle · doi:10.4161/cc.7.12.6161 · Cited by 92
p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3
Wong, R. P. C., Tsang, W. P., Chau, P. Y., Co, N. N., Tsang, T. Y., & Kwok, T. T. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0336 · Cited by 87 · cited 1×
“On the other hand, mutant p53 downregulates a variety of genes, many of which have play critical roles in GBM, including: CD95/Fas/Apo1 [57], transforming growth factor, beta receptor II [58], caspase-3 [59], p21, GADD45 (growth arrest and DNA damage-inducible), PERP (p53 apoptosis effector related to PMP22) and PTEN…”
BackgroundLányi, Á., Deb, D., Seymour, R. C., Ludes-Meyers, J. H., Subler, M. A., & Deb, S. (1998) · Oncogene · doi:10.1038/sj.onc.1201857 · Cited by 87
Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor
Stegh, A. H., Brennan, C., Mahoney, J. A., Forloney, K. L., Jenq, H. T., Luciano, J. P., Protopopov, A., Chin, L., & DePinho, R. A. (2010) · Genes & Development · doi:10.1101/gad.1924710 · Cited by 85
Holland, E. C., Li, Y., Celestino, J., Dai, C., Schaefer, L., Sawaya, R. A., & Fuller, G. N. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64615-9 · Cited by 81
Mutant p53 proteins bind DNA in a DNA structure-selective mode
G hler, T. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki252 · Cited by 76 · cited 1×
“Furthermore, mutant p53 has been shown to interact with DNA via the stereospecific configuration of non-B form DNA instead of response element DNA sequences [46, 47].”
BackgroundKarsy, M. J., Albert, L., Tobias, M. E., Murali, R., & Jhanwar‐Uniyal, M. (2010) · PubMed · Cited by 73
Self-citationBrázdová, M., Quante, T., Tögel, L., Walter, K., Loscher, C., Tichý, V., Činčárová, L., Deppert, W., & Tolstonog, G. V. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn1085 · Cited by 72 · cited 1×
“In GBM, analysis of genomic expression in a mutant p53 cell line (U251) indicated upregulation ofmultiple genes previously associated with tumorigenesis, including: JAK2 (janus kinase 2), C3ORF26, FRMD5 (FERM domain containing 5), CYFIP2 (cytoplasmic FMR1 interacting protein 2), neuregulin 1 (NRG1), PPARGC1A (peroxiso…”
BackgroundBeyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma
Stegh, A. H., & DePinho, R. A. (2011) · Cell Cycle · doi:10.4161/cc.10.1.14365 · Cited by 71
The p53 mutation “gradient effect” and its clinical implications
Zambetti, G. P. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21217 · Cited by 71
Kalo, E., Buganim, Y., Shapira, K. E., Besserglick, H., Goldfinger, N., Weisz, L., Stambolsky, P., Henis, Y. I., & Rotter, V. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00374-07 · Cited by 70
Marutani, M., Tonoki, H., Tada, M., Takahashi, M., Kashiwazaki, H., Hida, Y., Hamada, J. I., Asaka, M., & Moriuchi, T. (1999) · PubMed · Cited by 66
Structural biology of the p53 tumour suppressor
Okorokov, A. L., & Orlova, E. V. (2009) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2009.02.003 · Cited by 65 · cited 1×
“P53 contains 393 amino acids in four domains, a regulator domain (N-terminus) with adjacent proline-X-Xproline rich domain, core DNA-binding domain with nuclear localization signals, tetramerization domain, and a Cterminus [28].”
Backgroundp53 Increases Experimental Metastatic Capacity of Murine Carcinoma Cells
Pohl, J., Goldfinger, N., Radler‐Pohl, A., Rotter, V., & Schirrmacher, V. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.5.2078 · Cited by 62
Will, K., Warnecke, G., Wiesmüller, L., & Deppert, W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13681 · Cited by 61
Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9:138–41
Mao, L. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.16.1182 · Cited by 56
Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy
Shchors, K., Persson, A. I., Rostker, F., Tihan, T., Lyubynska, N., Li, N., Swigart, L. B., Berger, M. S., Hanahan, D., Weiss, W. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219142110 · Cited by 48
Molecular control of brain size: Regulators of neural stem cell life, death and beyond
Joseph, B., & Hermanson, O. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.03.012 · Cited by 39 · cited 1×
“The tumor-suppressive activities of p63/p73 act in a tissue-specific manner and may play a role in the development and regulation of NSC self-renewal and differentiation [36, 37].”
BackgroundIdentification of genomic DNA sequences bound by mutant p53 protein (Gly245→Ser) in vivo
Koga, H., & Deppert, W. (2000) · Oncogene · doi:10.1038/sj.onc.1203745 · Cited by 35 · cited 1×
“Furthermore, mutant p53 has been shown to interact with DNA via the stereospecific configuration of non-B form DNA instead of response element DNA sequences [46, 47].”
BackgroundLee, M. K., & Sabapathy, K. (2008) · Journal of Cell Science · doi:10.1242/jcs.022822 · Cited by 31
p53 regulates LIF expression in human medulloblastoma cells
Baxter, E. W., & Milner, J. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-0043-x · Cited by 26 · cited 1×
“P53 has also been shown to regulate expression of leukemia inhibitory factor, an important protein in embryonic growth/development, in vitro culture of CSCs, and neurosphere self-renewal [69].”
BackgroundLi, S., Jiang, T., Li, G., & Wang, Z. (2008) · Neurological Research · doi:10.1179/174313208x297913 · Cited by 25
High affinity MAR-DNA binding is a common property of murine and human mutant p53
Will, K., Warnecke, G., Albrechtsen, N., Boulikas, T., & Deppert, W. (1998) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19980601)69:3<260::aid-jcb4>3.0.co;2-p · Cited by 21
Oncogenomic Approaches in Exploring Gain of Function of Mutant p53
Donzelli, S., Biagioni, F., Fausti, F., Strano, S., Fontemaggi, G., & Blandino, G. (2008) · Current Genomics · doi:10.2174/138920208784340713 · Cited by 20 · cited 1×
“Recent advances in chromatin immunoprecipitation methodology has allowed for the evaluation of mutant p53 and chromatin interactions in a context-dependent manner [50].”
BackgroundPalani, M., Devan, S., Arunkumar, R., & Vanisree, A. J. (2011) · Medical Oncology · doi:10.1007/s12032-010-9671-4 · Cited by 10 · cited 1×
“Evidence of p63/p73 downregulation by p53 has been unable to fully explain GBM pathogenesis; however, promoter methylation of p63/p73 has been shown to correlate with increased tumor grade [40].”
Background
Cited by
Epidemiology of Glioblastoma Multiforme–Literature Review
Grochans, S., Cybulska, A. M., Simińska, D., Korbecki, J., Kojder, K., Chlubek, D., & Baranowska-Bosiacka, I. (2022) · Cancers · doi:10.3390/cancers14102412 · Cited by 630
“The inactivation of p53 correlates with increased invasiveness [49], decreased cell apoptosis [50], and increased proliferation [51].”
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440
“It is commonly activated in response to DNA damage, genotoxicity, oncogene activation, aberrant growth signals, and hypoxia, all of which are events that can be encountered during carcinogenesis [27].”
BackgroundInfluentialEmerging treatment strategies for glioblastoma multiforme
Carlsson, S. K., Brothers, S. P., & Wahlestedt, C. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201302627 · Cited by 365
“…may limit the therapeutic value of this target (Heimberger et al , 2005). p 53 and PTEN p53 is a well-known tumor suppressor protein that plays a fundamental role in the formation of high-grade tumors (England et al , 2013). p53 initiates DNA repair, or apoptosis if DNA damage is irrep-arable.”
Emerging Therapies for Glioblastoma
Thomas, A. A., Brennan, C. W., DeAngelis, L. M., & Omuro, A. M. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1701 · Cited by 167
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies
Garber, S. T., Hashimoto, Y., Weathers, S.-P., Xiu, J., Gatalica, Z., Verhaak, R. G. W., Zhou, S., Fuller, G. N., Khasraw, M., de Groot, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now132 · Cited by 139
Metadata
- Authors
- England, B., Huang, T., & Karsy, M.
- Affiliations
- New York Medical College (US)
- Corresponding author
- Karsy, Michael
- Venue
- Tumor Biology
- Published
- 2013-06-05
- Volume
- 34
- Issue
- 4
- Pages
- 2063-2074
- ISSN
- 1010-4283 (ISSN-L)
- 1423-0380
- OpenAlex
- W2004432187
- Cited by
- 163
- References
- 125
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 17 · 2023: 9 · 2022: 15 · 2021: 18 · 2020: 12 · 2019: 8 · 2018: 6 · 2017: 13 · 2016: 16 · 2015: 13 · 2014: 20 · 2013: 1
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Tumor Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- glioblastoma, p53, tumor suppressor, TP53 mutation, mutational hotspots, loss of function, gain-of-function, dominant-negative p53, MDM2, MDM4, p53 isoforms, miR-34, p63, p73, prognosis, cancer vaccination
- MeSH terms
- Animals, Brain Neoplasms, Glioblastoma, Humans, Prognosis, Signal Transduction, Tumor Suppressor Protein p53, Protein Isoforms, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.